<?xml version="1.0" encoding="UTF-8"?>
<p>In this paper we support the rationale for the use of statins, a class of drugs with widespread availability and an optimal tolerability profile, as an add-on treatment for COVID-19 patients, on the basis of their known immunomodulatory properties.</p>
